| Original language | English |
|---|---|
| Pages (from-to) | 1114-1115 |
| Number of pages | 2 |
| Journal | JAMA Oncology |
| Volume | 6 |
| Issue number | 7 |
| DOIs | |
| State | Published - 1 Jul 2020 |
Bibliographical note
Funding Information:Conflict of Interest Disclosures: Dr Hwang reported receiving grants from the Breast Cancer Research Foundation, National Institutes of Health, and Patient-Centered Outcomes Research Institute. Dr Thompson reported receiving travel fees from Pfizer. No other disclosures were reported.
Funding Information:
Conflict of Interest Disclosures: Dr Matsuo reported receiving an honorarium from Chugai, textbook editorial expense from Springer, and investigator meeting attendance expense from VBL Therapeutics outside the submitted work. Dr Matsuzaki reported receiving research grants from MSD outside the submitted work. Dr Klar reported receiving consultation fees from Tesaro and GSK outside the submitted work. Dr Roman reported receiving consultation fees from Quantgene outside the submitted work. Dr Sood reported receiving consultation fees from Merck and Kiyatec, being a shareholder for Bio-Path Holdings, and receiving research grants from M-Trap outside the submitted work. Dr Wright reported receiving grants from Merck and consultation fees from Clovis Oncology outside the submitted work. No other disclosures were reported. Funding/Support: This study was funded by grant NCI R01CA169121-01A1 from the National Cancer Institute (Dr Wright); grant NCI CA217685 from the National Cancer Institute, American Cancer Society, and the Frank McGraw Memorial Chair in Cancer Research (Dr Sood); and Ensign Endowment for Gynecologic Cancer Research (Dr Matsuo). Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
Additional Contributions: Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Andrew Gannon, MS, MA, of Cirrus Communications, an Ashfield company, and was funded by AstraZeneca.
Funding
Conflict of Interest Disclosures: Dr Hwang reported receiving grants from the Breast Cancer Research Foundation, National Institutes of Health, and Patient-Centered Outcomes Research Institute. Dr Thompson reported receiving travel fees from Pfizer. No other disclosures were reported. Conflict of Interest Disclosures: Dr Matsuo reported receiving an honorarium from Chugai, textbook editorial expense from Springer, and investigator meeting attendance expense from VBL Therapeutics outside the submitted work. Dr Matsuzaki reported receiving research grants from MSD outside the submitted work. Dr Klar reported receiving consultation fees from Tesaro and GSK outside the submitted work. Dr Roman reported receiving consultation fees from Quantgene outside the submitted work. Dr Sood reported receiving consultation fees from Merck and Kiyatec, being a shareholder for Bio-Path Holdings, and receiving research grants from M-Trap outside the submitted work. Dr Wright reported receiving grants from Merck and consultation fees from Clovis Oncology outside the submitted work. No other disclosures were reported. Funding/Support: This study was funded by grant NCI R01CA169121-01A1 from the National Cancer Institute (Dr Wright); grant NCI CA217685 from the National Cancer Institute, American Cancer Society, and the Frank McGraw Memorial Chair in Cancer Research (Dr Sood); and Ensign Endowment for Gynecologic Cancer Research (Dr Matsuo). Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Andrew Gannon, MS, MA, of Cirrus Communications, an Ashfield company, and was funded by AstraZeneca.
| Funders | Funder number |
|---|---|
| Ensign Endowment for Gynecologic Cancer Research | |
| National Institutes of Health | |
| American Cancer Society | |
| National Cancer Institute | NCI CA217685 |
| Breast Cancer Research Foundation | |
| AstraZeneca | |
| Merck | R01CA169121-01A1 |
| Patient-Centered Outcomes Research Institute | |
| Meso Scale Diagnostics |
